Vladislav A. Kalmykov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vladislav A. Kalmykov has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Nikolaevich Orekhov
Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia
10 shared publications - Vasiliy Nikolaevich Sukhorukov
Institute of General Pathology and Pathophysiology, Moscow, Russia
5 shared publications - Nikolay K. Shakhpazyan
Petrovsky National Research Centre of Surgery, Moscow, Russia
4 shared publications - Lyudmila Mikhaylovna Mikhaleva
Petrovsky National Research Centre of Surgery, Moscow, Russia
3 shared publications - Siarhei Alexander Dabravolski
Department of Biotechnology Engineering, Braude Academic College of Engineering, Snunit 51, P.O. Box 78, Karmiel 2161002, Israel
3 shared publications - Anastasia O. Maksaeva
Institute of General Pathology and Pathophysiology, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2196
Comparative Histopathological Characteristics of Duodenal Involvement in Different Types of Amyloidosis
Background/Objectives: The duodenum is commonly involved in systemic amyloidosis. This retrospective observational study describes histoanatomical distributions of different types of duodenal amyloidosis to improve the diagnostic value of duodenal biopsies. Methods: We examined 21 biopsy and 16 autopsy specimens from duodenal amyloidosis patients. Immunohistochemical typing was performed using a broad panel of antibodies against different amyloid types. Results: AL lambda amyloidosis was determined in 5 (13%) biopsies and 7 (18%) autopsies, exhibiting interstitial and intravascular amyloid deposition patterns in 11 (92%) cases; AL kappa amyloidosis—in 7 (18%) biopsies and 1 (3%) autopsy, presenting with a combined interstitial and intravascular deposition pattern in 6 (75%) cases; transthyretin amyloidosis—in 2 (5%) biopsies and 2 (5%) autopsies, showing focal interstitial and intravascular deposits; and AA amyloidosis—in 7 (19%) biopsies and 6 (16%) autopsies, demonstrating a combined pattern of amyloid deposition. Regardless of the specific amyloid type, in 33 (89%) of 37 cases, amyloid deposits were determined in the muscularis mucosae and submucosa of the small intestine, while in the lamina propria, amyloid depositions were found only in 29 (78%) cases. Conclusions: When diagnosing duodenal amyloidosis, superficial biopsies can lead to false negative results. This is particularly true for ATTR amyloidosis, where mucosal involvement is rare. The most extensive amyloid deposits were observed in AL kappa amyloidosis. Gastrointestinal bleeding was a more frequent complication of AA amyloidosis stemming from the extensive amyloid deposits within the lamina propria which cause vascular fragility and friability.
- 8 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2196
Open AccessComparative Histopathological Characteristics of Duodenal Involvement in Different Types of Amyloidosis
Background/Objectives: The duodenum is commonly involved in systemic amyloidosis. This retrospective observational study describes histoanatomical distributions of different types of duodenal amyloidosis to improve the diagnostic value of duodenal biopsies. Methods: We examined 21 biopsy and 16 autopsy specimens from duodenal amyloidosis patients. Immunohistochemical typing was performed using a broad panel of antibodies against different amyloid types. Results: AL lambda amyloidosis was determined in 5 (13%) biopsies and 7 (18%) autopsies, exhibiting interstitial and intravascular amyloid deposition patterns in 11 (92%) cases; AL kappa amyloidosis—in 7 (18%) biopsies and 1 (3%) autopsy, presenting with a combined interstitial and intravascular deposition pattern in 6 (75%) cases; transthyretin amyloidosis—in 2 (5%) biopsies and 2 (5%) autopsies, showing focal interstitial and intravascular deposits; and AA amyloidosis—in 7 (19%) biopsies and 6 (16%) autopsies, demonstrating a combined pattern of amyloid deposition. Regardless of the specific amyloid type, in 33 (89%) of 37 cases, amyloid deposits were determined in the muscularis mucosae and submucosa of the small intestine, while in the lamina propria, amyloid depositions were found only in 29 (78%) cases. Conclusions: When diagnosing duodenal amyloidosis, superficial biopsies can lead to false negative results. This is particularly true for ATTR amyloidosis, where mucosal involvement is rare. The most extensive amyloid deposits were observed in AL kappa amyloidosis. Gastrointestinal bleeding was a more frequent complication of AA amyloidosis stemming from the extensive amyloid deposits within the lamina propria which cause vascular fragility and friability.
- 27 March 2025
- Published by Springer Nature in Apoptosis
- Vol. 30 (5-6) , 1216-1234
Necroptosis in myocardial ischaemia-reperfusion injury: current update on mechanisms, therapeutic targets, and translational potential
Necroptosis is a programmed form of cell death that has gained significant attention in the field of cardiovascular research due to its involvement in myocardial infarction (MI) and myocardial ischaemia-reperfusion (I/R) injury. Unlike apoptosis, necroptosis elicits a pro-inflammatory response, contributing to myocardial injury, fibrosis, and adverse remodelling. This review aims to provide an overview of the molecular mechanisms underlying necroptosis, with a particular focus on its role in myocardial I/R injury. Key regulatory proteins such as Receptor-interacting protein kinase 3 (RIPK3) and Mixed lineage kinase domain-like protein (MLKL) are central to the necroptotic process, mediating cell death and inflammation. The review discusses the potential of targeting necroptosis as a therapeutic strategy for managing cardiovascular diseases, particularly post-MI. The RIPK3-CaMKII-mitochondrial permeability transition pore (mPTP) pathway is identified as a critical signalling axis in necroptosis and its inhibition may offer protective benefits in myocardial injury. The review also considers the role of natural and chemical inhibitors and other genes in necroptosis regulation. Overall, targeting necroptosis represents a promising avenue for therapeutic intervention to mitigate cardiac injury, promote recovery, and improve long-term patient outcomes in cardiovascular diseases.
- 27 March 2025
- Published by Springer Nature in Apoptosis
- Vol. 30 (5-6) , 1216-1234
Necroptosis in myocardial ischaemia-reperfusion injury: current update on mechanisms, therapeutic targets, and translational potential
Necroptosis is a programmed form of cell death that has gained significant attention in the field of cardiovascular research due to its involvement in myocardial infarction (MI) and myocardial ischaemia-reperfusion (I/R) injury. Unlike apoptosis, necroptosis elicits a pro-inflammatory response, contributing to myocardial injury, fibrosis, and adverse remodelling. This review aims to provide an overview of the molecular mechanisms underlying necroptosis, with a particular focus on its role in myocardial I/R injury. Key regulatory proteins such as Receptor-interacting protein kinase 3 (RIPK3) and Mixed lineage kinase domain-like protein (MLKL) are central to the necroptotic process, mediating cell death and inflammation. The review discusses the potential of targeting necroptosis as a therapeutic strategy for managing cardiovascular diseases, particularly post-MI. The RIPK3-CaMKII-mitochondrial permeability transition pore (mPTP) pathway is identified as a critical signalling axis in necroptosis and its inhibition may offer protective benefits in myocardial injury. The review also considers the role of natural and chemical inhibitors and other genes in necroptosis regulation. Overall, targeting necroptosis represents a promising avenue for therapeutic intervention to mitigate cardiac injury, promote recovery, and improve long-term patient outcomes in cardiovascular diseases.
- 1 January 2025
- Published by Eman Research Publishing LLC in Journal of Angiotherapy
- Vol. 9 (1) , 1-8
Autoimmunity and Chronic Inflammation in the Development of Atherosclerosis: New Treatment Strategies
Atherosclerosis, the leading cause of cardiovascular diseases, is a chronic inflammatory disorder driven by complex interactions between the innate and adaptive immune systems. Extensive research in both preclinical models and human studies has established the critical role of immune cells in sustaining vascular inflammation and promoting plaque development. Monocytes/macrophages, lymphocytes, neutrophils, mast cells, NK cells, and dendritic cells infiltrate atherosclerotic plaques, influencing disease progression through their activation and cytokine-mediated responses. Single-cell transcriptomic analyses have revealed distinct immune cell phenotypes, emphasizing their heterogeneity and functional dynamics in plaque formation, rupture, and resolution. Understanding the pathways involved in immune cell homing, activation, and regulation is essential for developing targeted therapies. Emerging anti-inflammatory interventions have shown promise in clinical trials, including IL-1β inhibitors (canakinumab), IL-6 antagonists (ziltivekimab), NLRP3 inflammasome inhibitors (colchicine, dapansutrile), and p38 MAPK inhibitors (losmapimod). These therapies aim to modulate inflammatory signaling and reduce cardiovascular risk. Additionally, nanoparticle-based imaging and drug delivery strategies are being explored to enhance precision medicine approaches in stabilizing plaques. However, balancing immune suppression with maintaining vascular homeostasis remains a challenge, necessitating further research to optimize therapeutic efficacy. This review provides an updated perspective on the immunological mechanisms underlying atherosclerosis and highlights novel anti-inflammatory strategies with potential clinical implications for cardiovascular disease management.
- 1 January 2025
- Published by Eman Research Publishing LLC in Journal of Angiotherapy
- Vol. 9 (1) , 1-8
Autoimmunity and Chronic Inflammation in the Development of Atherosclerosis: New Treatment Strategies
Atherosclerosis, the leading cause of cardiovascular diseases, is a chronic inflammatory disorder driven by complex interactions between the innate and adaptive immune systems. Extensive research in both preclinical models and human studies has established the critical role of immune cells in sustaining vascular inflammation and promoting plaque development. Monocytes/macrophages, lymphocytes, neutrophils, mast cells, NK cells, and dendritic cells infiltrate atherosclerotic plaques, influencing disease progression through their activation and cytokine-mediated responses. Single-cell transcriptomic analyses have revealed distinct immune cell phenotypes, emphasizing their heterogeneity and functional dynamics in plaque formation, rupture, and resolution. Understanding the pathways involved in immune cell homing, activation, and regulation is essential for developing targeted therapies. Emerging anti-inflammatory interventions have shown promise in clinical trials, including IL-1β inhibitors (canakinumab), IL-6 antagonists (ziltivekimab), NLRP3 inflammasome inhibitors (colchicine, dapansutrile), and p38 MAPK inhibitors (losmapimod). These therapies aim to modulate inflammatory signaling and reduce cardiovascular risk. Additionally, nanoparticle-based imaging and drug delivery strategies are being explored to enhance precision medicine approaches in stabilizing plaques. However, balancing immune suppression with maintaining vascular homeostasis remains a challenge, necessitating further research to optimize therapeutic efficacy. This review provides an updated perspective on the immunological mechanisms underlying atherosclerosis and highlights novel anti-inflammatory strategies with potential clinical implications for cardiovascular disease management.
- Open Access
- 5 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (9) , 5141
Novel Models of Crohn’s Disease Pathogenesis Associated with the Occurrence of Mitochondrial Dysfunction in Intestinal Cells
Crohn’s disease remains one of the challenging problems of modern medicine, and the development of new and effective and safer treatments against it is a dynamic field of research. To make such developments possible, it is important to understand the pathologic processes underlying the onset and progression of Crohn’s disease at the molecular and cellular levels. During the recent years, the involvement of mitochondrial dysfunction and associated chronic inflammation in these processes became evident. In this review, we discuss the published works on pathogenetic models of Crohn’s disease. These models make studying the role of mitochondrial dysfunction in the disease pathogenesis possible and advances the development of novel therapies.
- 5 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (9) , 5141
Open AccessNovel Models of Crohn’s Disease Pathogenesis Associated with the Occurrence of Mitochondrial Dysfunction in Intestinal Cells
Crohn’s disease remains one of the challenging problems of modern medicine, and the development of new and effective and safer treatments against it is a dynamic field of research. To make such developments possible, it is important to understand the pathologic processes underlying the onset and progression of Crohn’s disease at the molecular and cellular levels. During the recent years, the involvement of mitochondrial dysfunction and associated chronic inflammation in these processes became evident. In this review, we discuss the published works on pathogenetic models of Crohn’s disease. These models make studying the role of mitochondrial dysfunction in the disease pathogenesis possible and advances the development of novel therapies.
- Open Access
- 15 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 452
Functional Phenotypes of Intraplaque Macrophages and Their Distinct Roles in Atherosclerosis Development and Atheroinflammation
Macrophages are the key inflammatory cell type involved in all stages of atherosclerosis development and progression, as demonstrated by numerous studies. Correspondingly, macrophages are currently regarded as a promising therapeutic target for the development of new treatment approaches. The macrophage population is heterogeneous and dynamic, as these cells can switch between a number of distinct functional states with pro- and anti-atherogenic activity in response to various stimuli. An atherosclerotic plaque microenvironment defined by cytokine levels, cell-to-cell interactions, lipid accumulation, hypoxia, neoangiogenesis, and intraplaque haemorrhage may guide local macrophage polarization processes within the lesion. In this review, we discuss known functional phenotypes of intraplaque macrophages and their distinct contribution to ahteroinflammation.
- 15 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 452
Open AccessFunctional Phenotypes of Intraplaque Macrophages and Their Distinct Roles in Atherosclerosis Development and Atheroinflammation
Macrophages are the key inflammatory cell type involved in all stages of atherosclerosis development and progression, as demonstrated by numerous studies. Correspondingly, macrophages are currently regarded as a promising therapeutic target for the development of new treatment approaches. The macrophage population is heterogeneous and dynamic, as these cells can switch between a number of distinct functional states with pro- and anti-atherogenic activity in response to various stimuli. An atherosclerotic plaque microenvironment defined by cytokine levels, cell-to-cell interactions, lipid accumulation, hypoxia, neoangiogenesis, and intraplaque haemorrhage may guide local macrophage polarization processes within the lesion. In this review, we discuss known functional phenotypes of intraplaque macrophages and their distinct contribution to ahteroinflammation.
- Open Access
- 25 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1332
Cholesterol Transport Dysfunction and Its Involvement in Atherogenesis
Atherosclerosis is the cause of the development of serious cardiovascular disorders, leading to disability and death. Numerous processes are involved in the pathogenesis of atherosclerosis, including inflammation, endothelial dysfunction, oxidative stress, and lipid metabolism disorders. Reverse transport of cholesterol is a mechanism presumably underlying the atheroprotective effect of high-density lipoprotein. In this review, we examined disorders of cholesterol metabolism and their possible effect on atherogenesis. We paid special attention to the reverse transport of cholesterol. Transformed cholesterol metabolism results in dyslipidemia and early atherosclerosis. Reverse cholesterol transport is an endogenous mechanism by which cells export cholesterol and maintain homeostasis. It is known that one of the main factors leading to the formation of atherosclerotic plaques on the walls of blood vessels are multiple modifications of low-density lipoprotein, and the formation of foam cells following them.
- 25 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1332
Open AccessCholesterol Transport Dysfunction and Its Involvement in Atherogenesis
Atherosclerosis is the cause of the development of serious cardiovascular disorders, leading to disability and death. Numerous processes are involved in the pathogenesis of atherosclerosis, including inflammation, endothelial dysfunction, oxidative stress, and lipid metabolism disorders. Reverse transport of cholesterol is a mechanism presumably underlying the atheroprotective effect of high-density lipoprotein. In this review, we examined disorders of cholesterol metabolism and their possible effect on atherogenesis. We paid special attention to the reverse transport of cholesterol. Transformed cholesterol metabolism results in dyslipidemia and early atherosclerosis. Reverse cholesterol transport is an endogenous mechanism by which cells export cholesterol and maintain homeostasis. It is known that one of the main factors leading to the formation of atherosclerotic plaques on the walls of blood vessels are multiple modifications of low-density lipoprotein, and the formation of foam cells following them.
- Top Cited PapersOpen Access
- 24 January 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 254
The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy
Kruppel like factor 2 (KLF2) is a mechanosensitive transcription factor participating in the regulation of vascular endothelial cells metabolism. Activating KLF2 in endothelial cells induces eNOS (endothelial nitric oxide synthase) expression, subsequent NO (nitric oxide) release, and vasodilatory effect. In addition, many KLF2-regulated genes participate in the anti-thrombotic, antioxidant, and anti-inflammatory activities, thereby preventing atherosclerosis development and progression. In this review, we summarise recent evidence suggesting that KLF2 plays a major role in regulating atheroprotective effects in endothelial cells. We also discuss several recently identified repurposed drugs and natural plant-based bioactive compounds with KLF2-mediated atheroprotective activities. Herein, we present a comprehensive overview of the role of KLF2 in atherosclerosis and as a pharmacological target for different drugs and natural compounds and highlight the potential application of these phytochemicals for the treatment of atherosclerosis.
- 24 January 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 254
Top Cited PapersOpen AccessThe Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy
Kruppel like factor 2 (KLF2) is a mechanosensitive transcription factor participating in the regulation of vascular endothelial cells metabolism. Activating KLF2 in endothelial cells induces eNOS (endothelial nitric oxide synthase) expression, subsequent NO (nitric oxide) release, and vasodilatory effect. In addition, many KLF2-regulated genes participate in the anti-thrombotic, antioxidant, and anti-inflammatory activities, thereby preventing atherosclerosis development and progression. In this review, we summarise recent evidence suggesting that KLF2 plays a major role in regulating atheroprotective effects in endothelial cells. We also discuss several recently identified repurposed drugs and natural plant-based bioactive compounds with KLF2-mediated atheroprotective activities. Herein, we present a comprehensive overview of the role of KLF2 in atherosclerosis and as a pharmacological target for different drugs and natural compounds and highlight the potential application of these phytochemicals for the treatment of atherosclerosis.
- Open Access
- 21 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1153
Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis
For more than a decade, atherosclerosis has been one of the leading causes of death in developed countries. The issue of treatment and prevention of the disease is especially acute. Despite the huge amount of basic and clinical research, a significant number of gaps remain in our understanding of the pathogenesis of atherosclerosis, and only their closure will bring us closer to understanding the causes of the disease at the cellular and molecular levels and, accordingly, to the development of an effective treatment. One of the seemingly well-studied elements of atherogenesis is the mTOR signaling pathway. However, more and more new details are still being clarified. Therapeutic strategies associated with rapamycin have worked well in a number of different diseases, and there is every reason to believe that targeting components of the mTOR pathway may pay off in atherosclerosis as well.
- 21 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1153
Open AccessModulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis
For more than a decade, atherosclerosis has been one of the leading causes of death in developed countries. The issue of treatment and prevention of the disease is especially acute. Despite the huge amount of basic and clinical research, a significant number of gaps remain in our understanding of the pathogenesis of atherosclerosis, and only their closure will bring us closer to understanding the causes of the disease at the cellular and molecular levels and, accordingly, to the development of an effective treatment. One of the seemingly well-studied elements of atherogenesis is the mTOR signaling pathway. However, more and more new details are still being clarified. Therapeutic strategies associated with rapamycin have worked well in a number of different diseases, and there is every reason to believe that targeting components of the mTOR pathway may pay off in atherosclerosis as well.
- Open Access
- 16 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 952
The Role of Mitochondrial DNA Mutations in Cardiovascular Diseases
Cardiovascular diseases (CVD) are one of the leading causes of morbidity and mortality worldwide. mtDNA (mitochondrial DNA) mutations are known to participate in the development and progression of some CVD. Moreover, specific types of mitochondria-mediated CVD have been discovered, such as MIEH (maternally inherited essential hypertension) and maternally inherited CHD (coronary heart disease). Maternally inherited mitochondrial CVD is caused by certain mutations in the mtDNA, which encode structural mitochondrial proteins and mitochondrial tRNA. In this review, we focus on recently identified mtDNA mutations associated with CVD (coronary artery disease and hypertension). Additionally, new data suggest the role of mtDNA mutations in Brugada syndrome and ischemic stroke, which before were considered only as a result of mutations in nuclear genes. Moreover, we discuss the molecular mechanisms of mtDNA involvement in the development of the disease.
- 16 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 952
Open AccessThe Role of Mitochondrial DNA Mutations in Cardiovascular Diseases
Cardiovascular diseases (CVD) are one of the leading causes of morbidity and mortality worldwide. mtDNA (mitochondrial DNA) mutations are known to participate in the development and progression of some CVD. Moreover, specific types of mitochondria-mediated CVD have been discovered, such as MIEH (maternally inherited essential hypertension) and maternally inherited CHD (coronary heart disease). Maternally inherited mitochondrial CVD is caused by certain mutations in the mtDNA, which encode structural mitochondrial proteins and mitochondrial tRNA. In this review, we focus on recently identified mtDNA mutations associated with CVD (coronary artery disease and hypertension). Additionally, new data suggest the role of mtDNA mutations in Brugada syndrome and ischemic stroke, which before were considered only as a result of mutations in nuclear genes. Moreover, we discuss the molecular mechanisms of mtDNA involvement in the development of the disease.
- Open Access
- 15 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 931
The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets
The vascular endothelial growth factor (VEGF) family, the crucial regulator of angiogenesis, lymphangiogenesis, lipid metabolism and inflammation, is involved in the development of atherosclerosis and further CVDs (cardiovascular diseases). This review discusses the general regulation and functions of VEGFs, their role in lipid metabolism and atherosclerosis development and progression. These functions present the great potential of applying the VEGF family as a target in the treatment of atherosclerosis and related CVDs. In addition, we discuss several modern anti-atherosclerosis VEGFs-targeted experimental procedures, drugs and natural compounds, which could significantly improve the efficiency of atherosclerosis and related CVDs’ treatment.
- 15 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 931
Open AccessThe Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets
The vascular endothelial growth factor (VEGF) family, the crucial regulator of angiogenesis, lymphangiogenesis, lipid metabolism and inflammation, is involved in the development of atherosclerosis and further CVDs (cardiovascular diseases). This review discusses the general regulation and functions of VEGFs, their role in lipid metabolism and atherosclerosis development and progression. These functions present the great potential of applying the VEGF family as a target in the treatment of atherosclerosis and related CVDs. In addition, we discuss several modern anti-atherosclerosis VEGFs-targeted experimental procedures, drugs and natural compounds, which could significantly improve the efficiency of atherosclerosis and related CVDs’ treatment.